Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost

2018 ◽  
Vol 179 (1) ◽  
pp. 208-209 ◽  
Author(s):  
S. Norrenberg ◽  
M. Masconi ◽  
M. Karamanou ◽  
P. Meylan ◽  
R. Golaz ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Treatment Effectiveness ◽  
Complex Evaluation

Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study

Epilepsia ◽  
2021 ◽  
Vol 62 (3) ◽  
pp. 785-794
Author(s):  
Jakob Stockinger ◽  
Adam Strzelczyk ◽  
Andrea Nemecek ◽  
Michal Cicanic ◽  
Frank Bösebeck ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Complex Patients ◽  
Patients With Epilepsy

24988 Spectrum of facial angiofibromas in 85 patients with tuberous sclerosis complex in a tertiary hospital. Retrospective study and revision of the literature

2021 ◽  
Vol 85 (3) ◽  
pp. AB51
Author(s):  
Pablo Cobo Rodríguez ◽  
Pablo Boixeda De Miquel ◽  
Iván Checa Recio ◽  
Jaime Martínez Mariscal ◽  
Raquel Cabana Navia ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Tertiary Hospital

scholarly journals Everolimus Versus Sirolimus for Angiomyolipoma Associated with Tuberous Sclerosis Complex: A Multi-Institutional Retrospective Study in China

2021 ◽  
Author(s):  
luo cong ◽  
Yu-shi Zhang ◽  
Ming-Xin Zhang ◽  
Min-Feng Chen ◽  
Yuan Li ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Adverse Events ◽  
Tuberous Sclerosis ◽  
Oral Mucositis ◽  
Tuberous Sclerosis Complex ◽  
National Cancer Institute ◽  
Therapeutic Efficacy ◽  
Efficacy And Safety ◽  
First Choice ◽  
Significant Difference

Abstract Purpose To evaluate the efficacy and safety of everolimus and sirolimus in patients with tuberous sclerosis complex-associated angiomyolipomas (TSC-AML). Materials and Methods We performed a multi-institutional retrospective study of TSC-AML patients treated with oral everolimus or sirolimus. Angiomyolipoma volume was estimated using orthogonal measurements by MRI or CT. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events. All analyses were performed using SPSS 19.0 software. Results There were high response rates in both two groups. With the prolonged medication time, the therapeutic efficacy of two agents became more significant. Everolimus had a more significant TSC-AML volume reduction after 6 and 12 months than sirolimus. More than 1/2 of everolimus patients had ≥ 50% reduction and approximately 80% of them had ≥ 30% reduction, higher than that of the sirolimus patients. Regarding safety, there was no significant difference in the incidence of AEs between the two groups. And the most common AE was oral mucositis. Conclusions Both everolimus and sirolimus are excellent therapeutic choices for TSC-AML. However, everolimus had a better therapeutic efficacy than sirolimus, especially in reducing TSC-AML volume. Therefore, everolimus is recommended as the first choice.

scholarly journals Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Cong Luo ◽  
Yu-Shi Zhang ◽  
Ming-Xin Zhang ◽  
Min-Feng Chen ◽  
Yuan Li ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Adverse Events ◽  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
National Cancer Institute ◽  
Therapeutic Efficacy ◽  
Efficacy And Safety ◽  
First Choice ◽  
Significant Difference ◽  
Choice Of Therapy

Abstract Purpose To evaluate the efficacy and safety of everolimus and sirolimus in patients with tuberous sclerosis complex-associated angiomyolipomas (TSC-AML). Materials and methods We performed a multi-institutional retrospective study of TSC-AML patients treated with oral everolimus 10 mg or sirolimus 2 mg per day for at least 3 months. Angiomyolipoma volume was estimated using orthogonal measurements by MRI or CT. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events. All analyses were performed using SPSS 19.0 software. Results Response rates were high in both groups. With the prolonged medication durations, the therapeutic efficacy of both agents became more significant. The TSC-AML volume reduction after 6 and 12 months was more pronounced in patients with everolimus than those with sirolimus. More than half of the patients treated with everolimus had ≥ 50% reduction, and approximately 80% of them had ≥ 30% reduction, which was higher than that in patients treated with sirolimus. Regarding safety, there was no significant difference in the incidence of AEs between the two groups. Conclusions Both everolimus and sirolimus are excellent therapeutic options for TSC-AML. However, everolimus has a better therapeutic efficacy than sirolimus, particularly in reducing TSC-AML volume. Everolimus is therefore recommended as the first choice of therapy for TSC-AML.

Predictors of Efficacy in Patients with Adjunctive Everolimus Therapy for Treatment-Resistant Seizures Associated with Tuberous Sclerosis Complex

2017 ◽  
Vol 48 (S 01) ◽  
pp. S1-S45
Author(s):  
G. Wiegand ◽  
T. Polster ◽  
C. Hertzberg ◽  
A. Wiemer-Kruel ◽  
J. French ◽  
...  
Keyword(s):  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Treatment Resistant

Everolimus Reduces Seizure Frequency in Tuberous Sclerosis Complex

2017 ◽  
Vol 48 (S 01) ◽  
pp. S1-S45
Author(s):  
T. Stapper ◽  
D. Valcheva ◽  
T. Höll ◽  
T. Rosenbaum
Keyword(s):  
Tuberous Sclerosis ◽  
Seizure Frequency ◽  
Tuberous Sclerosis Complex

Good seizure outcome after epilepsy surgery in young children with tuberous sclerosis complex

2006 ◽  
Vol 37 (03) ◽  
Author(s):  
C Krahn-Peper ◽  
IEB Tuxhorn ◽  
K Ahlbory ◽  
F Behne ◽  
H Pannek
Keyword(s):  
Young Children ◽  
Tuberous Sclerosis ◽  
Epilepsy Surgery ◽  
Tuberous Sclerosis Complex ◽  
Seizure Outcome
Sign in / Sign up

Export Citation Format

Share Document